Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

37 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Potential use of lymph node-derived HPV-specific T cells for adoptive cell therapy of cervical cancer.
van Poelgeest MI, Visconti VV, Aghai Z, van Ham VJ, Heusinkveld M, Zandvliet ML, Valentijn AR, Goedemans R, van der Minne CE, Verdegaal EM, Trimbos JB, van der Burg SH, Welters MJ. van Poelgeest MI, et al. Among authors: visconti vv. Cancer Immunol Immunother. 2016 Dec;65(12):1451-1463. doi: 10.1007/s00262-016-1892-8. Epub 2016 Sep 12. Cancer Immunol Immunother. 2016. PMID: 27619514 Free PMC article.
Long-term Survival and Clinical Benefit from Adoptive T-cell Transfer in Stage IV Melanoma Patients Is Determined by a Four-Parameter Tumor Immune Signature.
Melief SM, Visconti VV, Visser M, van Diepen M, Kapiteijn EH, van den Berg JH, Haanen JB, Smit VT, Oosting J, van der Burg SH, Verdegaal EM. Melief SM, et al. Among authors: visconti vv. Cancer Immunol Res. 2017 Feb;5(2):170-179. doi: 10.1158/2326-6066.CIR-16-0288. Epub 2017 Jan 10. Cancer Immunol Res. 2017. PMID: 28073773
The Thirteenth International Conference on Progress in Vaccination Against Cancer (PIVAC-13), October 2-4, 2013, Amsterdam, The Netherlands: the current standing of anti-tumor immunotherapeutic approaches.
Melief SM, Visconti VV, Doorduijn EM, Santegoets SJ. Melief SM, et al. Among authors: visconti vv. Cancer Immunol Immunother. 2014 Oct;63(10):1105-12. doi: 10.1007/s00262-014-1532-0. Epub 2014 Mar 12. Cancer Immunol Immunother. 2014. PMID: 24619351 Free PMC article. No abstract available.
Triple peptide vaccination as consolidation treatment in women affected by ovarian and breast cancer: Clinical and immunological data of a phase I/II clinical trial.
Antonilli M, Rahimi H, Visconti V, Napoletano C, Ruscito I, Zizzari IG, Caponnetto S, Barchiesi G, Iadarola R, Pierelli L, Rughetti A, Bellati F, Panici PB, Nuti M. Antonilli M, et al. Int J Oncol. 2016 Apr;48(4):1369-78. doi: 10.3892/ijo.2016.3386. Epub 2016 Feb 8. Int J Oncol. 2016. PMID: 26892612 Free PMC article. Clinical Trial.
Monoclonal antibodies in gynecological cancer: a critical point of view.
Bellati F, Napoletano C, Gasparri ML, Visconti V, Zizzari IG, Ruscito I, Caccetta J, Rughetti A, Benedetti-Panici P, Nuti M. Bellati F, et al. Clin Dev Immunol. 2011;2011:890758. doi: 10.1155/2011/890758. Epub 2011 Dec 26. Clin Dev Immunol. 2011. PMID: 22235224 Free PMC article. Review.
Immune effects of trastuzumab.
Nuti M, Bellati F, Visconti V, Napoletano C, Domenici L, Caccetta J, Zizzari IG, Ruscito I, Rahimi H, Benedetti-Panici P, Rughetti A. Nuti M, et al. J Cancer. 2011;2:317-23. doi: 10.7150/jca.2.317. Epub 2011 May 25. J Cancer. 2011. PMID: 21716848 Free PMC article.
HPV induced triple neoplasms: a case report.
Visconti V, Antonilli M, Bellati F, Napoletano C, French D, Benedetti Panici P, Nuti M. Visconti V, et al. Am J Obstet Gynecol. 2009 Aug;201(2):e9-e12. doi: 10.1016/j.ajog.2009.05.008. Am J Obstet Gynecol. 2009. PMID: 19646562
37 results